Theranostic application of nanomedicine in neurodegenerative diseases: Current and future perspectives
Nanotheranostics for Diagnosis and Therapy, Page: 221-248
2024
- 18Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures18
- Readers18
- 18
Book Chapter Description
Nanotechnology, operating at the nano-scale level (1-100 nm), offers innovative solutions in designing polymeric materials for molecular interactions with biological systems. These materials show potential in targeted drug delivery, minimizing adverse effects, and enhancing therapeutic efficacy, specifically in neurodegenerative disorders, i.e., Parkinson's disease (PD) and Alzheimer's disease (AD). However, delivering of drugs to the brain is one of the key challenging due to the blood-brain barrier's (BBB) restrictive nature. Strategies to overcome this barrier include using lipophilic analogues, prodrugs, and chemical drug delivery systems. Carrier-mediated and receptor/vector-mediated delivery exploit existing transport systems, while nanoparticle-mediated delivery efficiently transports drugs across the BBB. Nanotechnology holds vast potential in healthcare, bioscience, and medicine, with nanomedicine offering innovative solutions to conventional medicine's challenges. Utilizing multifunctional nanocarriers for targeted drug delivery and imaging, especially in treating neurodegenerative diseases, holds significant promise. The emergence of theranostic nanomedicines could revolutionize clinical trials in the future.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85208778471&origin=inward; http://dx.doi.org/10.1007/978-981-97-3115-2_9; https://link.springer.com/10.1007/978-981-97-3115-2_9; https://dx.doi.org/10.1007/978-981-97-3115-2_9; https://link.springer.com/chapter/10.1007/978-981-97-3115-2_9
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know